The Stasis ION™ System.
MicroAmino's pre-filled cartridges, pens, and nasal/oral sprays are formulated with the Stasis ION™ System — a cGMP protic ionic liquid (PIL) excipient platform engineered to stabilize peptides and enhance mucosal permeation in research models, without enzymatic degradation or loss of structural integrity.
The data below is preclinical, third-party characterization of the delivery excipient, provided for research context only. It is not a medical, therapeutic, or performance claim about any product. Research Use Only — professional / physician use only.
How long Stasis ION™ protects peptides.
Peptides are fragile — they degrade with heat, agitation, and enzymatic attack. In independent third-party HPLC testing, peptide formulated in the Stasis ION™ matrix held its potency at room temperature across a multi-month study.
- ✓ 101.1–101.9% recovery by HPLC — no measurable loss of potency
- ✓ 4-month room-temperature stability study
- ✓ No cold chain required for the Stasis ION™ matrix itself
- ✓ Protease inhibition & aggregation control at the molecular level
room-temperature stable
A multi-mechanism delivery matrix.
The Stasis ION™ System organizes the formulation into nano-scale ionic assemblies that protect the peptide and move it across mucosal barriers in research models.
Molecular stabilization
Protic ionic liquid network inhibits proteases and controls aggregation, preserving peptide structure.
Sub-10 nm assemblies
A confirmed 5–10 nm secondary population (DLS) small enough to penetrate mucus gel networks that trap conventional formulations.
Mucus viscosity reduction
Reduces mucosal viscosity and modulates epithelial tight junctions (TEER reversibility) to open a transient permeation path.
Naturally-occurring build
Built from citric acid (a Krebs-cycle metabolite) + lysine & arginine — GRAS and USP/NF status, no novel synthetic entities.
The numbers.
Produced under cGMP.
The Stasis ION™ System is manufactured under an NSF-assessed cGMP quality system in California.
- ✓ Manufactured in an NSF/ANSI 455-2 (2024) certified facility
- ✓ 21 CFR Part 111, Part 117, Part 11 in scope
- ✓ Formulation, encapsulation, packaging & QC under one quality unit
- ✓ Every MicroAmino batch ships with a third-party COA
Certified facility
Manufactured under an NSF-assessed cGMP quality system in Rancho Cucamonga, CA. The facility holds NSF/ANSI 455-2 certification; its scope includes 21 CFR Parts 111, 117, 11, 1.5 Subpart L & 1.9 Subpart O.
Powered by Stasis ION™.
Every pre-filled format in the MicroAmino catalog is built on the Stasis ION™ System.
References & scope. Third-party studies: Zhejiang TianMei Biological Engineering Co., LTD and Zhejiang University of Technology. Peer-reviewed class reference: Angsantikul et al., Advanced Functional Materials (DOI: 10.1002/adfm.202002912). Data is preclinical; no human clinical data. Provided for laboratory research context only — not a medical, therapeutic, or performance claim.